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Systemic amyloidoses result from the aberrant
secretion of destabilized, amyloidogenic proteins to
the serumwhere they aggregate into proteotoxic sol-
uble aggregates and amyloid fibrils. Few therapeutic
approaches exist to attenuate extracellular patho-
logic aggregation of amyloidogenic proteins, neces-
sitating the development of new strategies to inter-
vene in these devastating disorders. We show that
stress-independent activation of the Unfolded Pro-
tein Response-associated transcription factor ATF6
increases ER quality control stringency for the amy-
loidogenic protein transthyretin (TTR), preferentially
reducing secretion of disease-associated TTR vari-
ants to an extent corresponding to the variants’
destabilization of the TTR tetramer. This decrease
in destabilized TTR variant secretion attenuates
extracellular, concentration-dependent aggregation
of amyloidogenic TTRs into soluble aggregates
commonly associated with proteotoxicity in disease.
Collectively, our results indicate that increasing ER
quality control stringency through ATF6 activation
is a strategy to attenuate pathologic aggregation of
a destabilized, amyloidogenic protein, revealing a
potential approach to intervene in systemic amyloid
disease pathology.
INTRODUCTION
The ER is the primary organelle responsible for the folding and
trafficking of proteins destined for downstream environments
of the secretory pathway, including the extracellular space.
Newly synthesized proteins are cotranslationally translocated
into the ER lumen, where ER chaperones and folding enzymes
facilitate their proper folding into native 3D conformations (Gi-
dalevitz et al., 2013; Kleizen and Braakman, 2004). Once
folded, these proteins are directed to coat protein complex II
vesicles for trafficking to downstream secretory environments1564 Chemistry & Biology 21, 1564–1574, November 20, 2014 ª2014(D’Arcangelo et al., 2013). Proteins unable to properly fold
in the ER lumen are targeted to ER degradation pathways
including ER-associated degradation (ERAD) and autophagy
(Brodsky and Skach, 2011). This partitioning of ER targeted
polypeptides between ER protein folding/trafficking and degra-
dation pathways, also referred to as ER quality control, pre-
vents the ER accumulation and secretion of misfolding-prone
proteins that could aggregate into pathologic proteotoxic con-
formations (Brodsky and Skach, 2011; Gidalevitz et al., 2013;
Powers et al., 2009).
While ER quality control is generally efficient at preventing the
secretion of aggregation-prone proteins, the aberrant secretion
of destabilized, amyloidogenic proteins is pathologically associ-
ated with >13 protein misfolding diseases including the systemic
amyloidoses (Blancas-Mejı´a and Ramirez-Alvarado, 2013). In
these diseases, efficient secretion of destabilized, amyloido-
genic proteins leads to their extracellular, concentration-depen-
dent assembly into proteotoxic soluble aggregates and amyloid
fibrils that deposit on tissues distal from the site of protein
synthesis, leading to organ malfunction and eventual death (Gill-
more and Hawkins, 2013). The dependence of pathologic extra-
cellular protein aggregation on the secretion of destabilized,
amyloidogenic proteins indicates that inadequate ER quality
control stringency directly contributes to disease pathogenesis
(Kleizen and Braakman, 2004; Sekijima et al., 2005; Wiseman
et al., 2007).
The importance of ER quality control in the pathology of sys-
temic amyloid diseases is most evident in the transthyretin
(TTR) amyloidoses, a set of familial systemic amyloid disorders
causally linked to the aberrant hepatic secretion of >100 desta-
bilized TTR variants (Johnson et al., 2012). Highly destabilized,
highly aggregation-prone TTR variants such as TTRD18G and
TTRA25T are recognized by the liver’s ER quality control path-
ways and targeted to degradation in the ER (Hammarstro¨m
et al., 2003; Sato et al., 2007; Sekijima et al., 2003, 2005). The
increased partitioning of destabilized TTR variants to ER degra-
dation pathways decreases their secretion and reduces their
serum concentrations, attenuating pathologic concentration-
dependent TTR aggregation in the serum. As such, patients
expressing highly destabilized TTR mutations present with mod-
erate disease pathologies inconsistent with the high amyloido-
genicity of these variants (Hammarstro¨m et al., 2003; SekijimaElsevier Ltd All rights reserved
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highly amyloidogenic, TTR variants such as TTRL55P are effi-
ciently secreted from the liver, resulting in high serum concentra-
tions that facilitate pathologic aggregation into proteotoxic solu-
ble aggregates (Hammarstro¨m et al., 2002; Sekijima et al., 2005).
Owing to the failure of ER quality control to prevent the secretion
of these more moderately destabilizing TTR variants, individuals
harboring mutations of this type present with the most severe
and earliest-onset systemic amyloid disease pathology (Ham-
marstro¨m et al., 2002; Jacobson et al., 1992). A similar relation-
ship between ER quality control stringency and amyloidogenic
protein secretion has been proposed to explain the variable dis-
ease pathologies associated with other systemic amyloidoses
(Kumita et al., 2006; Marchesi et al., 2011). The relationship be-
tween ER quality control of amyloidogenic proteins and amyloid
disease pathology suggests that increasing ER quality control
stringency to reduce the secretion of destabilized protein vari-
ants is a potential strategy to attenuate the extracellular protein
aggregation responsible for disease pathogenesis.
Many of the protein factors responsible for maintaining ER
quality control stringency are transcriptional targets of the ER
unfolded protein response (UPR) (Walter and Ron, 2011). The
UPR consists of three integrated signaling pathways activated
downstream of the ER transmembrane proteins IRE1, activating
transcription factor 6 (ATF6), and PERK. These pathways are
activated in response to the accumulation of misfolded proteins
within the ER lumen (i.e., ER stress), resulting in transient
translational attenuation (downstream of PERK) and the tran-
scriptional remodeling of ER protein folding, trafficking, and
degradation pathways. UPR-dependent remodeling of these
ER proteostasis pathways is primarily achieved through the
two UPR-associated transcription factors spliced XBP1
(XBP1s, activated downstream of IRE1) and ATF6 (a cleaved
product of full length ATF6) that induce overlapping, but distinct,
sets of ER proteostasis factors (Adachi et al., 2008; Shoulders
et al., 2013; Yamamoto et al., 2004). This indicates that activation
of XBP1s and/or ATF6 offers a unique opportunity to differentially
influence ER quality control of destabilized amyloidogenic pro-
tein variants.
Previously, we showed that stress-independent ATF6 activa-
tion reduces secretion of destabilized amyloidogenic TTRA25T
(Shoulders et al., 2013). Here, we show that ATF6 activation simi-
larly attenuates secretion of other destabilized, amyloidogenic
TTR variants through a mechanism involving the increased par-
titioning of destabilized TTR monomers to degradation. Intrigu-
ingly, we show a sigmoidal relationship between the impact of
ATF6 activation on TTR variant secretion and the destabilization
of the TTR variant tetramer, demonstrating that ATF6-dependent
remodeling of the ER proteostasis environment preferentially
reduces secretion of destabilized, aggregation-prone TTRs.
Furthermore, we show that the capacity for ATF6 activation to
reduce secretion and hence extracellular concentrations of ag-
gregation-prone TTR variants also decreases their extracellular
aggregation into proteotoxic soluble aggregates. Collectively,
our results demonstrate that increasing ER quality control strin-
gency through stress-independent ATF6 activation is a viable
strategy to decrease secretion and consequent extracellular ag-
gregation of destabilized TTR variants responsible for the patho-
genesis of familial TTR amyloidoses.Chemistry & Biology 21, 1564–157RESULTS
ATF6 Activation Preferentially Reduces Secretion of
Disease-Associated TTR Variants
We previously showed that ATF6 activation reduces the secre-
tion of the disease-associated TTRA25T (Shoulders et al., 2013).
To evaluate whether ATF6 activation similarly affects the secre-
tion of other disease-associated, amyloidogenic TTR variants,
we chose five TTR variants that predispose patients to varying
levels of amyloid disease pathology: TTRD18G and TTRA25T
(poorly secreted TTR variants that present with moderate dis-
ease pathology, see Hammarstro¨m et al., 2003; Sekijima
et al., 2003; Vidal et al., 1996), TTRL55P (the TTR variant that
presents with the most severe TTR amyloid disease in patients,
see Hammarstro¨m et al., 2002; Jacobson et al., 1992), TTRV30M
(the most prominent TTR variant in patients that presents with
varying disease pathologies within endemic populations, see
Buxbaum et al., 2010), and TTRV122I (a TTR variant found in
5% of the African American population that presents with a
late onset cardiac disease pathology, see Buxbaum et al.,
2006). We also chose two TTR variants that do not cause famil-
ial TTR amyloidoses: wild-type TTR (TTRWT) and TTRT119M
(a highly stabilized TTR variant that transsuppresses TTR amy-
loid disease in heterozygote patients, see Hammarstro¨m et al.,
2001).
We used [35S] metabolic labeling to measure the secretion of
FLAG tagged TTR (FTTTR) variants from human embryonic kid-
ney (HEK)293DAX cells (Figure S1A available online). These cells
stably and constitutively express a protein fusion between de-
stabilized dihydrofolate reductase (DHFR) and the active ATF6
transcription factor (DHFR.ATF6) that is rapidly degraded by
the proteasome (Figure 1A) (Shoulders et al., 2013). The addition
of the small molecule DHFR pharmacologic chaperone trimeth-
oprim (TMP) stabilizes the DHFR.ATF6 fusion protein, prevents
proteasomal degradation, and promotes transcriptional activity
of DHFR.ATF6 (Figure 1A). Thus, in HEK293DAX, the ATF6 tran-
scriptional program can be activated in the absence of ER stress
through TMP-dependent DHFR.ATF6 stabilization (Shoulders
et al., 2013).
We found that FTTTR variants are secreted from HEK293DAX
with identical efficiencies to those previously reported for BHK
cells (Figures 1B–1H and S1A–S1C) (Sekijima et al., 2005).
FTTTRD18G and FTTTRA25T are poorly secreted from HEK293DAX
cells, demonstrating secretion efficiencies of 6% and 27%,
respectively, following a 4 hr chase in nonradioactive media
(Figures 1B and 1C and S1B and S1C). Conversely, other
FTTTR variants were secreted to levels nearly identical to those
observed for FTTTRWT, demonstrating 60% secretion effi-
ciency following a 4 hr chase (Figures 1D–1H). ATF6 preactiva-
tion results in a significant 40% decrease in the secretion
of the disease-associated variants FTTTRD18G, FTTTRA25T,
FTTTRL55P, and FTTTRV30M and a 30% decrease in FTTTRV122I
secretion. Alternatively, the secretion of FTTTRWT and the highly
stable FTTTRT119M were only modestly reduced by 15%
following ATF6 preactivation. These results show that ATF6
preactivation preferentially reduces the secretion of amyloido-
genic TTR variants associated with familial TTR amyloid dis-
eases relative to FTTTRWT and the nonpathogenic FTTTRT119M
(Figure 1I).4, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1565
Figure 1. Stress-Independent ATF6 Preactivation Preferentially
Decreases Secretion of Disease-Associated TTR Variants
(A) Schematic illustrating the TMP-mediated, posttranslational regulation of
DHFR.ATF6 in HEK293DAX cells (Shoulders et al., 2013).
(B–H) Quantification of fraction secreted [35S]-labeled FTTTR variants from
HEK293DAXcells in theabsence (black) or presence (blue) ofATF6preactivation
(TMP, 10 mM; 16 hr). Representative autoradiograms and the experimental
protocol are shown in Figure S1A. Fraction secreted was calculated from au-
toradiograms using the equation: Fraction Secreted = {Total FTTTR Signal in
Media at Time = t } divided by {Total FTTTR Signal in Lysate at Time = 0} + {Total
FTTTRSignal inMedia at Time =0} (Sekijima et al., 2005; Shoulders et al., 2013).
Error bars represent SEM from biological replicates (nR 3). Identical plots of
fraction secreted for FTTTRD18G and FTTTRA25T with the same scales used for
the other TTR variants are shown in Figures S1B and S1C.
(I) Bar graph comparing fraction secreted at 4 hr for FTTTR variants in the
absence (gray) or presence of ATF6 preactivation (blue), as shown in Figures
1B–1H. Shading shows familial disease-associated FTTTR variants (pink) and
FTTTR variants not involved in familial disease (brown). Error bars represent
SEM from biological replicates (nR 3).
**p < 0.01; ***p < 0.001.
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Activation Follows a Sigmoidal Relationship with
Energetic Stability
The partitioning of TTR between ER protein folding/trafficking
and degradation is influenced by the thermodynamic (the equi-
librium propensity to attain a folded conformation) and kinetic1566 Chemistry & Biology 21, 1564–1574, November 20, 2014 ª2014(the rate of interconversion between folded and unfolded confor-
mations) stabilities of the TTR tetramer (Sekijima et al., 2005).
Previously, the secretion of TTR variants from mammalian cells
was shown to depend on their stability as expressed by the com-
bined stability score (CSS), an energetic parameter determined
by a linear regression against in vitro-derived thermodynamic
(Cm of urea denaturation) and kinetic (t1/2 of tetramer dissocia-
tion/unfolding) measures of TTR variant stability (Sekijima
et al., 2005) (Table S1). We find a similar dependence of FTTTR
variant secretion on CSS in the absence or presence of ATF6
activation (Figure 2A). The FoldEx mathematical model for
protein secretion predicts a sigmoidal relationship between the
energetic stability and fraction secreted for a given series of de-
stabilized variants of a single protein (Wiseman et al., 2007). This
sigmoidal relationship has been previously indicated for destabi-
lized variants of monomeric TTR (M-TTR), bovine pancreatic
trypsin inhibitor, and lysozyme (Kumita et al., 2006; Wiseman
et al., 2007) and reflects the energetically defined partitioning
of protein variants between ER protein folding, trafficking, and
degradation pathways (Wiseman et al., 2007). We find that the
relationship between FTTTR variant energetic stability (defined
by the CSS) and fraction secreted is also consistent with a sig-
moid (Figure 2A). Interestingly, ATF6 activation appears to shift
the sigmoidal transition to higher CSS values, indicating that
ATF6 activation preferentially decreases the partitioning of de-
stabilized FTTTR variants to ER trafficking pathways and in-
creases the energetic requirements for TTR variant secretion
(Powers et al., 2009; Wiseman et al., 2007).
To better visualize the effect of ATF6 activation on the secre-
tion of destabilized FTTTR variants, we plotted the impact of
ATF6 activation (defined as [fraction TTR variant secretion at
4 hr in the presence of ATF6 preactivation]/[fraction TTR variant
secretion at 4 hr in the absence of ATF6 activation]) against the
CSS for TTR variants (Figure 2B). As a ratio of two sigmoids,
this plot is also sigmoidal. This relationship shows that ATF6 acti-
vation influences FTTTR variant secretion to extents defined by
the inherent instability of the protein fold (described by the CSS).
ATF6 Activation Increases Targeting of Destabilized
TTR Monomers to ER Degradation Pathways
ER quality control is defined by the partitioning of destabilized,
misfolding-prone proteins between secretion and degradation
in the ER lumen. The results shown in Figure 2 indicate that
ATF6 activation reduces FTTTR variant secretion to levels
dictated by the energetic destabilization of the protein fold,
showing that ATF6 activation increases ER quality control strin-
gency for TTR (i.e., the energetic requirements for TTR variant
secretion). We next tested whether ATF6 preactivation also
influenced the partitioning of destabilized TTR variants to
degradation.
We measured ATF6-dependent increases in TTR degradation
by monitoring the fraction of total [35S]-labeled TTR (media +
lysates) remaining following a 4 hr chase in the experiments
shown in Figures 1 and S1. ATF6 preactivation reduced the re-
covery of destabilized FTTTRD18G, FTTTRA25T, FTTTRL55P, and
FTTTRV30M (Figure 3A), without increasing intracellular levels of
these variants (Figure S2A). The recovery of the more stable
FTTTRV122I, FTTTRWT, and FTTTRT119M were not affected by
ATF6 preactivation. Interestingly, the relationship between theElsevier Ltd All rights reserved
Figure 2. The ATF6-Dependent Decrease in Destabilized TTR
Variant Secretion Correlates with the Energetic Stability of the TTR
Tetramer
(A) Plot relating the TTR variant CSS as calculated in (Sekijima et al., 2005)
(Table S1) to the fraction FTTTR variant secreted at 4 hr in the absence (black)
or presence (blue) of ATF6 preactivation. The solid circles show the average for
all replicates and the open circles show all individual replicates. The error bars
show SEM for nR 3. The curves describe the least-squares fit of the individual
replicates to the sigmoid function (defined in Experimental Procedures).
(B) Plot relating the TTR variant CSS as calculated in (Sekijima et al., 2005)
(Table S1) to the impact of ATF6 activation on FTTTR variant secretion. The
impact of ATF6 activation on FTTTR variant secretion is defined as {fraction
FTTTR secretion at 4 hr in the presence of ATF6 preactivation} divided by
{fraction FTTTR secretion at 4 hr in the absence of ATF6 preactivation}. The
solid circles show the average impact of ATF6 activation for all replicates and
the open circles show all individual replicates. The error bars show SEM for n
R 3. The line describes the least-squares fit of the individual replicate data to
the sigmoid function defined in Experimental Procedures.
Chemistry & Biology
ATF6 Decreases TTR Variant SecretionTTR variant CSS and the impact of ATF6 activation on FTTTR
variant recovery shows that ATF6 activation preferentially re-
duces the recovery of the most destabilized TTR variants (Fig-
ure 3B). This suggests that ATF6 preactivation preferentially
increases partitioning of destabilized FTTTR variants toward
degradation, preventing the ER accumulation of these aggrega-
tion prone proteins that could disrupt ER proteostasis and func-
tion. Consistent with this prediction, we previously showed that
ATF6 activation does not increase the accumulation of destabi-
lized FTTTRA25T in insoluble aggregates (Shoulders et al., 2013).
ER degradation can occur through ERAD or autophagic path-
ways (Brodsky and Wojcikiewicz, 2009; Houck and Cyr, 2012).
We evaluated the contributions of these two pathways to the
ATF6-dependent increase in destabilized TTR degradation usingChemistry & Biology 21, 1564–157FTTTRD18G, a highly destabilized TTR variant that does not form
stable TTR tetramers (Hammarstro¨m et al., 2003). TTRD18G is a
known ERAD substrate that is degraded >50% in mammalian
cells (Sato et al., 2007; Sekijima et al., 2005; Shoulders et al.,
2013). Thus, as expected, the recovery of [35S]-metabolically
labeled FTTTRD18G in the absence of ATF6 preactivation is
modestly increased by the addition of the proteasome inhibitor
MG132 (Figures S2B and S2C). Interestingly, FTTTRD18G recov-
ery was similarly increased upon addition of NH4Cl, an inhibitor
of lysosomal degradation, suggesting that FTTTRD18G also can
be degraded through autophagic pathways (Figures S2B and
S2C). These results suggest that ATF6 activation could increase
FTTTRD18G degradation by increasing the partitioning of destabi-
lized TTRs to ERAD and/or autophagic pathways.
Surprisingly, the recovery of FTTTRD18G following ATF6 preac-
tivation does not appear to be affected by the addition of either
MG132 or NH4Cl (Figures 3C and S2B). Alternatively, coadminis-
tration ofMG132 andNH4Cl increased the recovery of
FTTTRD18G
by 30% following ATF6 preactivation. This result suggests that
ATF6 activation can increase the partitioning of FTTTRD18G to
ERAD and autophagic pathways, and that inhibition of either
pathway independently results in increased flux through the
alternative pathway (Lamark and Johansen, 2010).
Since TTRD18G exists as a destabilized monomer (Hammar-
stro¨m et al., 2003), we evaluated whether a stable monomeric
TTR (M-TTR, see Jiang et al., 2001) is also affected by ATF6 acti-
vation. M-TTR tetramerization is inhibited by two mutations at
the dimer interface, resulting in amonomeric TTRwhose stability
is identical to unassembled TTRWT subunits. Although ATF6 pre-
activation reduces FTM-TTR secretion by 30% (Figure S2D),
FTM-TTR is not significantly degraded upon ATF6 preactivation
(Figure 3D). This suggests that ATF6-dependent increases in de-
stabilized TTR degradation require destabilization of the mono-
mer. Collectively, the above results suggest a model whereby
enhanced ER quality control stringency for TTR upon ATF6 acti-
vation proceeds, at least in part, through increased partitioning
of destabilized FTTTR monomers to ERAD and/or autophagic
ER degradation pathways.
ATF6 Activation Reduces Secretion of Destabilized
FTTTRA25T from Liver-Derived HepG2 Cells
In heterozygote patients, TTR can be secreted as heterote-
tramers, comprised of TTR variant and TTRWT subunits (Fig-
ure 4A), the stability of which correlates with the number of
TTRWT subunits (Sekijima et al., 2005). This heterotetrameriza-
tion with TTRWT subunits stabilizes and promotes the secretion
of destabilized TTR variants such as TTRA25T (Sekijima et al.,
2005). Since our results indicate that ATF6 activation increases
degradation of destabilized TTR monomers prior to tetrameriza-
tion, we predicted that ATF6 activation would decrease secre-
tion of destabilized TTR variant subunits in TTRWT-containing
heterotetramers.
We employed a human, liver-derived HepG2 cell line stably
expressing DHFR.ATF6 (HepG2DA) to test this prediction
(Shoulders et al., 2013). HepG2 cells secrete high levels of
endogenous TTRWT, as liver cells are the primary secretory
tissue for TTR in vivo (Johnson et al., 2012). We previously
showed that ATF6 activation does not significantly influence
secretion of endogenous TTRWT from HepG2DA (Shoulders4, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1567
Figure 3. Stress-Independent ATF6 Pre-
activation Increases Partitioning ofDestabi-
lized TTR Monomers to ER Degradation
Pathways
(A) Bar graph comparing the fraction remaining of
[35S]-labeled FTTTR variants at 4 hr in the absence
(gray) or presence (blue) of ATF6 preactivation.
Fraction remaining was calculated from autora-
diograms as shown in Figure S1A, using the
equation: Fraction Remaining = {Total FTTTR
Signal in Lysate at Time = t } + {Total FTTTR Signal
in Media at Time = t } divided by {Total FTTTR
Signal in Lysate at Time = 0 } + {Total FTTTR Signal
in Media at Time = 0 } (Sekijima et al., 2005;
Shoulders et al., 2013). Shading shows familial
disease-associated FTTTR variants (pink) and
FTTTR variants not involved in familial disease
(brown). Error bars represent SEM from biological
replicates (nR 3).
(B) Plot relating the impact of ATF6 activation on
the fraction remaining for FTTTR variants, as
shown in Figure 3A, to each respective TTR vari-
ants’ CSS (Table S1). The impact of ATF6 activa-
tion on FTTTR variant fraction remaining is defined
as {fraction FTTTR remaining t = 4 hr in the pres-
ence of ATF6} divided by {fraction FTTTR remain-
ing t = 4 hr in the absence of ATF6}. Error bars
represent SEM from biological replicates (nR 3).
(C) Quantification of fraction remaining for [35S]-labeled FTTTRD18G in HEK293DAX following ATF6 preactivation (10 mMTMP; 16 hr) when chased in the presence of
vehicle (black), MG132 (10 mM; orange), NH4Cl (25 mM; green), or both MG132 and NH4Cl (purple). A representative autoradiogram and experimental protocol
employed are shown in Figure S2A. Error bars represent SEM from biological replicates (nR 3).
(D) Quantification of fraction remaining of [35S]-labeled FTM-TTR in HEK293DAX in the absence (black) or presence (blue) of ATF6 preactivation (10 mMTMP; 16 hr).
A representative autoradiogram is shown in Figure S2D. Error bars represent SEM from biological replicates (n = 6).
*p < 0.05, **p < 0.01, ***p < 0.001.
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ing FTTTRWT or FTTTRA25T, titered to allow identical expression
of FTTTR variants and endogenous TTRWT to mimic TTR expres-
sion in heterozygote patient livers (Figure 4B). Endogenous
TTRWT and exogenous FTTTR separate on SDS-PAGE, allowing
quantification of the FTTTR variants independent of the endog-
enous protein (Sekijima et al., 2005; Shoulders et al., 2013).
We measured the impact of ATF6 activation on the secretion
of FTTTR variants using a [35S] metabolic labeling approach, im-
munopurifying the FTTTR protein with a FLAG tag antibody. The
efficient formation of heterotetramers containing TTRWT and
FTTTR subunits in these cells is evident by the coimmunopurifi-
cation of endogenous TTRWT in our FLAG immunopurifications
(Figure S3A).
The preactivation of ATF6 in HepG2DA reduces secretion of
FTTTRA25T by 50% (Figure 4C). This decrease in FTTTRA25T secre-
tion corresponds with increased degradation of FTTTRA25T (Fig-
ure 4D). The secretion and degradation of FTTTRWT was only
modestly affected by ATF6 preactivation in HepG2DA cells (Fig-
ures 4E–4G). The degradation of FTTTRA25T in HepG2DA cells in
the presence or absence of ATF6 preactivation is attenuated
upon the addition of both MG132 and NH4Cl, but not upon the
addition of either inhibitor independently (Figures S3B and
S3C). This suggests that FTTTRA25T degradation in liver-derived
HepG2DA cells is mediated through the activities of ERAD and
autophagic pathways. This also suggests that ATF6-dependent
reductions in FTTTRA25T secretion from HepG2DA cells involves
increased partitioning of destabilized, FTTTRA25T monomers to1568 Chemistry & Biology 21, 1564–1574, November 20, 2014 ª2014ER degradation pathways. With less FTTTRA25T available, we ex-
pected that ATF6 activation would reduce secretion of TTR
heterotetramers that contain three or four FTTTRA25T subunits
relative to those that contain one or two FTTTRA25T subunits (Fig-
ure 4A), effectively increasing the kinetic stability of the secreted
TTR population (Johnson et al., 2012). Consistent with this pre-
diction, we observe an ATF6-dependent increase in the recovery
of [35S]-labeled TTRWT in FLAG-immunopurification of FTTTRA25T
from the experiments described in Figure 4D, which suggests an
ATF6-dependent increase in extracellular populations of tetra-
mers containing one or two FTTTRA25T subunits (Figure S3D).
These findings support our model, whereby ATF6 activation re-
duces TTR variant secretion through a mechanism involving
the increased targeting of destabilized TTR monomers to ER
degradation pathways prior to tetramer assembly.
Kinetic Stabilization of the TTR Tetramer Does Not
Inhibit ATF6-Dependent Reductions in Destabilized
Transthyretin Secretion
Small molecule TTR kinetic stabilizers such as Tafamidis (Taf)
bind to the native TTR tetramer and increase the energetic bar-
rier for TTR tetramer disassembly, thus preventing a requisite
step in the TTR amyloid cascade (Bulawa et al., 2012). We
applied Taf to further evaluate the capacity for ATF6 activation
to reduce FTTTR secretion by targeting destabilized FTTTR
monomers to degradation prior to tetramer assembly. Since
Taf stabilizes the TTR tetramer, but does not bind to the mono-
mer prior to assembly, we predicted that, in the presence ofElsevier Ltd All rights reserved
Figure 4. ATF6 Preactivation Decreases
Secretion of the Destabilized FTTTRA25T
Variant from Liver-Derived HepG2DA Cells
Coexpressing Equal Amounts of Endoge-
nous TTRWT
(A) Schematic of TTR heterotetramer formation
and secretion from HepG2DA cells expressing
endogenous TTRWT and FTTTR variants.
(B) Quantitative PCR (qPCR) analysis of TTR in
HepG2DA cells transduced with adenovirus en-
coding FTTTR variants. qPCR data is normalized
relative to mock-transfected HepG2DA cells. Error
bars represent 95% confidence interval for tech-
nical replicates.
(C and D) Plots showing fraction secreted (C) or
fraction remaining (D) of FTTTRA25T in HepG2DA in
the absence (black) or presence (blue) of ATF6
preactivation (10 mM TMP; 16 hr). A representa-
tive autoradiogram is shown in Figure S3A. Error
bars represent SEM from biological replicates
(n = 6).
(E and F) Plots showing the fraction secreted (E) or
fraction remaining (F) of FTTTRWT in HepG2DA in
the absence (black) or presence (blue) of ATF6
preactivation (10 mM TMP; 16 hr). A representative
autoradiogram is shown in Figure S3A. Error bars
represent SEM from biological replicates (n = 6).
(G) Graph showing the normalized fraction
secreted of FTTTRWT (gray) or FTTTRA25T (red) at
4 hr from HepG2DA in the absence or presence of
ATF6 preactivation, as shown in Figures 4C and
4E. Error bars represent SEM from biological
replicates (n = 6).
*p < 0.05, **p < 0.01, ***p < 0.001.
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secretion of destabilized FTTTR variants.
We tested this prediction in HEK293DAX cells overexpressing
destabilized FTTTRL55P. The tetramer dissociation rate of TTRL55P
is slow (t1/2 = 4.4 hr) relative to the rate of secretion (Sekijima et al.,
2005). This implies that stabilization of TTRL55P tetramers by Taf
should not influence the distribution of tetramers and monomers
in the steady-state environment of the ER, as any protein that
forms a tetramerwill be secreted prior to dissociation (Figure 5A).
The addition of Taf does not influence FTTTRL55P secretion in the
absence of ATF6 preactivation (Figures 5B, 5C, and S4A).
Furthermore, the addition of Taf does not affect the ATF6-depen-
dent decrease in FTTTRL55P secretion. These results indicate
that kinetic stabilization of the FTTTRL55P tetramer does not
influence ATF6-dependent reductions in TTR variant secretion,
supporting ourmodel, whereby ATF6 activation influences FTTTR
secretion prior to tetramerization.
We next evaluated the capacity for Taf and/or ATF6 activation
to influence the secretion of FTTTRA25T, a TTR tetramer that has
a fast tetramer dissociation rate relative to secretion (t1/2 =Chemistry & Biology 21, 1564–1574, November 20, 2014 ª0.035 hr) (Sekijima et al., 2005). The rapid
tetramer dissociation rate of TTRA25T
allows equilibration between TTR tetra-
mers and monomers in the ER prior to
secretion (Figure 5D). As shown previ-
ously (Shoulders et al., 2013), the addi-tion of Taf increases FTTTRA25T secretion from HEK293DAX cells
in the absence of ATF6 preactivation, demonstrating that Taf-
dependent stabilization of FTTTRA25T tetramers in the ER in-
creases secretion of this variant from mammalian cells (Figures
5E, 5F, and S4B). The capacity for Taf to influence FTTTRA25T
secretion demonstrates that FTTTRA25T tetramer dissociation in-
fluences the conformational distribution of FTTTRA25T tetramers
and monomers in the ER. The preactivation of ATF6 attenuates
the Taf-dependent increase in FTTTRA25T secretion, although Taf
does increase FTTTRA25T secretion relative to cells treated with
ATF6 preactivation alone (Figures 5E and 5F). Thus, even
though Taf stabilizes FTTTRA25T tetramers in the ER lumen,
ATF6 activation still reduces FTTTRA25T secretion, further sup-
porting our model wherein ATF6 activation influences secretion
of destabilized TTR prior to tetramerization.
ATF6-Dependent Reduction in Destabilized TTR
Secretion Attenuates Extracellular Aggregation of TTR
Extracellular aggregation of TTR into proteotoxic soluble aggre-
gates and amyloid fibrils is dependent on two parameters: the2014 Elsevier Ltd All rights reserved 1569
Figure 5. ATF6 Preactivation Decreases Secretion of Destabilized
FTTTR Variants in the Presence of the Small Molecule TTR Tetramer
Kinetic Stabilizer Tafamidis
(A) Illustration showing the folding, assembly, secretion, and Taf binding for
TTRL55P in the ER lumen. Note that the rate of TTRL55P tetramer dissociation is
slow relative to the rate of secretion, indicating that the effect of Taf binding on
the ER population of TTR tetramers will be negligible.
(B) Plot showing fraction FTTTRL55P secretion from HEK293DAX cells in the
absence of ATF6 preactivation (black), the presence of ATF6 preactivation
(10 mM TMP; 16 hr; blue), in the presence of Taf included in the pretreatment
and the chase media (10 mM 16 hr; green), or in the presence of ATF6 pre-
activation where Taf was added during the preincubation and the chase media
(brown). A representative autoradiogram and the experimental protocol em-
ployed are shown in Figure S4A. Error bars represent SEM from biological
replicates (n = 6).
(C) Bar graph depicting the normalized fraction secreted for FTTTRL55P at 4 hr as
shown in Figure 5B. Error bars represent SEM from biological replicates (n = 6).
(D) Illustration showing the folding, assembly, secretion, and Taf binding for
TTRA25T in the ER lumen. Note that the rate of TTRA25T tetramer dissociation is
fast relative to the rate of secretion, indicating that Taf can bind to and stabilize
TTRA25T tetramers in the ER lumen increasing TTRA25T secretion.
(E) Plot showing fraction FTTTRA25T secretion from HEK293DAX cells in the
absence of ATF6 preactivation (black), the presence of ATF6 preactivation
(10 mM TMP; 16 hr; blue), in the presence of Taf included in the pretreatment
and the chase media (10 mM 16 hr; green), or in the presence of ATF6 pre-
activation where Taf was added during the preincubation and the chase media
(brown). Error bars represent SEM from biological replicates (n = 3).
(F) Bar graph depicting the normalized fraction secreted for FTTTRA25T at 4 hr as
shown in Figure 5E. Error bars represent SE from biological replicates (n = 3).
**p < 0.01.
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1570 Chemistry & Biology 21, 1564–1574, November 20, 2014 ª2014destabilization of the TTR tetramer afforded by the mutation and
the extracellular concentration of destabilized TTR available for
concentration-dependent aggregation (Hammarstro¨m et al.,
2002) (Figure 6A). The capacity for ATF6 activation to preferen-
tially reduce secretion of destabilized TTR variants directly ad-
dresses both of these parameters. The aggregation propensity
for TTR was previously shown to inversely correlate with the
CSS of the TTR variant tetramer (Sekijima et al., 2005). Since
ATF6-dependent reductions in FTTTR variant secretion also re-
lates to the CSS, ATF6 activation should preferentially impact
secretion of amyloidogenic TTR variants. This effect is observed
in our experimental results as the impact of ATF6 activation on
FTTTR variant secretion inversely correlates with the optimal
pH of TTR fibril formation (Figure 6B), an in vitro-derivedmeasure
of TTR variant aggregation propensity (Sekijima et al., 2005). The
correlation shown in Figure 6B demonstrates that ATF6 activa-
tion preferentially reduces extracellular concentrations of the
most amyloidogenic TTR variants. Since no mouse model of
TTR familial amyloidosis recapitulates disease pathology (Bux-
baum et al., 2003), we evaluated the potential for ATF6 activation
to attenuate extracellular aggregation of secreted, destabilized
FTTTR variants into proteotoxic soluble aggregates, which are
predicted to be the proximal cause of TTR amyloid disease pa-
thology (Reixach et al., 2004).
Wemeasured the aggregation of FTTTR variants in conditioned
media using Clear-Native PAGE (CN-PAGE) (Upadhaya et al.,
2012). Destabilized FTTTRA25T secreted from HEK293T cells
spontaneously aggregates into soluble aggregates with molecu-
lar weights between 200–900 kDa (Figure 6C). This aggregation
is dependent on the amount of FTTTRA25T secreted from the cells,
as evidenced by the reduced aggregate concentrations in media
conditioned on cells transfected with decreasing amounts of
FTTTRA25T DNA. FTTTRA25T soluble aggregates were also identi-
fied by gel filtration chromatography (Figure S5A). Cell secreted
FTTTRWT does not efficiently form soluble aggregates (Figures
6C and S5A). Identical results were observed using the anti-
TTR antibody in CN-PAGE/immunoblotting assays (Figure S5B).
The addition of the TTR tetramer kinetic stabilizer Taf to
cells secreting FTTTRA25T inhibits TTR aggregation (Figure 6D),
demonstrating that the observed aggregation requires rate-
limiting dissociation of the TTR tetramer (Johnson et al., 2012).
Taf similarly reduced the extracellular aggregation of other de-
stabilized, aggregation-prone TTR variants (Figure S5B). The
activation of ATF6 during the conditioning of media prepared
on HEK293DAX cells expressing FTTTRA25T reduces FTTTRA25T
soluble aggregates by 50%, consistent with the ATF6-depen-
dent reduction in total FTTTRA25T secreted into the media
(Figure 6E). ATF6 activation similarly reduces extracellular solu-
ble aggregates of FTTTRD18G, FTTTRL55P, and FTTTRV30M (Fig-
ure S5C). These results indicate that reducing secretion of
destabilized, amyloidogenic FTTTR variants through stress-inde-
pendent ATF6 activation can decrease extracellular populations
of soluble TTR aggregates predicted to induce distal proteotox-
icity in TTR amyloid disease pathology (Reixach et al., 2004).
DISCUSSION
The extracellular aggregation of destabilized, amyloidogenic
protein variants is pathologically linked to the onset andElsevier Ltd All rights reserved
Figure 6. ATF6 Activation Attenuates the
Extracellular Concentration of Soluble
FTTTR Aggregates in Conditioned Media
(A) Illustration showing that the partitioning of
destabilized TTRs between degradation and
secretion in the ER impacts the extracellular con-
centration of aggregation-prone protein available
for concentration-dependent aggregation into
proteotoxic soluble aggregates.
(B) Plot comparing the impact of ATF6 activation
on FTTTR variant fraction secreted to the optimal
pH for TTR variant fibril formation determined in
(Sekijima et al., 2005) and shown in Table S1.
(C) CN-PAGE/immunoblot (IB) of media condi-
tioned for 24 hr on HEK293T cells overexpressing
FTTTRWT or FTTTRA25T following transfection with
the indicated equivalents of plasmid DNA. An
SDS-PAGE/IB of identical samples is shown as a
control for total FTTTR levels in the conditioned
media for each treatment.
(D) CN-PAGE/IB of media conditioned for 24 hr on
HEK293DAX cells transfected with one equivalent
of FTTTRA25T and treated with vehicle or 10 mM Taf
during conditioning, as indicated. An SDS-PAGE/
IB of identical samples is shown as a control for
total FTTTR levels in the conditioned media for
each treatment.
(E) Representative CN-PAGE/IB and quantifica-
tion of FTTTRA25T soluble aggregates in media
conditioned for 24 hr on HEK293DAX cells trans-
fected with one equivalent of FTTTRA25T in the
absence or presence of ATF6 activation (TMP;
10 mM) as indicated. An SDS-PAGE/IB of identical
samples is shown as a control for total FTTTR
levels in the conditionedmedia for each treatment.
Error bars represent SEM for n = 3.
**p < 0.01
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cas-Mejı´a and Ramirez-Alvarado, 2013). Because protein aggre-
gation is concentration-dependent, high serum concentrations
of destabilized amyloidogenic proteins facilitate their aggrega-
tion into proteotoxic soluble aggregates and amyloid fibrils,
directly contributing to disease pathogenesis. Thus, reducing
serum concentrations of destabilized proteins will attenuate
pathologic extracellular protein aggregation involved in systemic
amyloid disease pathogenesis (Ryno et al., 2013).
A strategy to reduce serum concentrations of amyloidogenic
proteins is to increase ER quality control in cells secreting desta-
bilized, disease-associated variants of amyloidogenic proteins.
ER protein secretion models predict that increasing ER quality
control stringency through adaptation of ER proteostasis path-
ways can preferentially attenuate secretion of destabilized
protein variants without significantly affecting secretion of the
stable, WT protein (Wiseman et al., 2007). This increase in ER
quality control stringency can be reflected by a shift in the
sigmoidal relationship between secretion efficiency and ener-
getic stability for a series of destabilized variants of a single pro-
tein (Figure 7A). Since amyloidogenicity often correlates with
protein destabilization (Blancas-Mejı´a and Ramirez-Alvarado,
2013; Jahn and Radford, 2005; Johnson et al., 2012), reducing
the secretion of destabilized protein variants by increasing ER
quality control stringency will decrease their extracellular popu-Chemistry & Biology 21, 1564–157lations available for concentration-dependent aggregation and
attenuate extracellular aggregate load (Figure 7B).
Here, we demonstrate that stress-independent ATF6 activa-
tion increases ER quality control stringency for the amyloido-
genic protein TTR, preferentially reducing the secretion of
destabilized, familial disease-associated TTR variants. ATF6
activation decreases TTR variant secretion to extents defined
by the inherent destabilization of the TTR tetramer, reflecting
the shift in ER quality control stringency described in Figure 7A.
The capacity for ATF6 activation to preferentially reduce secre-
tion of destabilized TTR variants based on energetic stability
demonstrates that this approach is broadly applicable to reduce
secretion of the remaining >100 destabilized, amyloidogenic
TTR variants involved in familial TTR amyloid disease pathology
(Johnson et al., 2012). Furthermore, we show that ATF6-depen-
dent reduction in the secretion of destabilized FTTTRs decreases
extracellular concentrations of soluble TTR aggregates, reflect-
ing the capacity for increased ER quality stringency to influence
extracellular aggregate load predicted in Figure 7B.
The increased ER quality control stringency for TTR observed
upon ATF6 activation corresponds with an increased partitioning
of destabilized TTRs to ERAD and autophagic degradation
pathways. Using monomeric TTR, heterotetramerization with
TTRWT, and a small molecule TTR tetramer stabilizer, we demon-
strate that ATF6-dependent increases in TTR degradation4, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1571
Figure 7. Increasing ER Quality Control Stringency Is a Viable
Therapeutic Approach to Reduce Extracellular Concentrations of
Proteotoxic Aggregates
(A) Illustration showing that adapting the ER proteostasis environment to
enhance ER quality control stringency can reduce secretion of destabilized
amyloidogenic protein variants (red) without significantly impacting secretion
of stable, WT protein (black).
(B) Illustration showing that increasing ER quality control stringency through
the adaption of the ER proteostasis environment provides a therapeutic
approach to preferentially reduce the extracellular aggregation of destabilized,
aggregation-prone protein variants most commonly associated with disease
pathogenesis (red). Highly destabilized protein variants are recognized by ER
quality control pathways, increasing their degradation in the ER, decreasing
their secretion to the extracellular space, and reducing extracellular concen-
trations available for concentration-dependent aggregation (left arrow).
Alternatively, stable protein variants prevent the initial misfolding steps
required for protein aggregation (right arrow).
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increased partitioning of destabilized TTR monomers to ER
degradation pathways. This indicates that ATF6-dependent in-
creases in ER quality control do not result in the intracellular
accumulation of destabilized, aggregation-prone TTR mono-
mers that could aggregate into toxic conformations, disrupt ER
proteostasis, and/or reduce cellular viability (Powers et al.,
2009). Furthermore, ATF6 activation increases degradation and
reduces secretion of destabilized TTRs in liver-derived HepG2DA
cells, indicating that this approach is likely applicable in hetero-
zygote patient livers, where destabilized TTRs can be stabilized
and trafficked to the extracellular space in heterotetramers
otherwise composed of TTRWT subunits.
The ATF6 transcriptional program has evolved to increase ER
quality control during ER stress and prevent the secretion of
misfolded protein conformations to the extracellular space
where they could aggregate into proteotoxic conformations.
Our results demonstrate that we can exploit this evolved function
of ATF6 to alter the partitioning of proteins between ER protein
folding/secretion and degradation based primarily on protein
stability. Consistent with this prediction, ATF6 activation reduces1572 Chemistry & Biology 21, 1564–1574, November 20, 2014 ª2014secretion and/or intracellular aggregation of aggregation-prone
variants of a1-antitrypsin and rhodopsin that are associated
with nonamyloidogenic protein aggregation diseases without
affecting trafficking of the corresponding stable, WT proteins
(Chiang et al., 2012; Smith et al., 2011). Furthermore, ATF6 acti-
vation does not globally impact secretion of the endogenous
secreted proteome (Shoulders et al., 2013). These results
suggest that stress-independent ATF6 activation offers a unique
opportunity to increase ER quality control stringency for destabi-
lized, misfolding-prone proteins without significant conse-
quences on the secretion and/or extracellular function of the
endogenous secreted proteome. Critically, overexpression of
the prominent ATF6 target gene BiP, the central HSP70 chap-
erone in the ER, attenuates degradation of destabilized TTR var-
iants without influencing TTR secretion (Susuki et al., 2009). This
suggests that emergent properties of global ER proteostasis re-
modeling afforded by ATF6 activation are distinct from those
accessible through targeting specific ER proteostasis factors,
further highlighting the advantage of accessing the endogenous
ATF6 transcriptional program to influence ER proteostasis of
aggregation-prone proteins.
The capacity for stress-independent activation of ATF6 to in-
crease ER quality control stringency for TTR suggests that
similar approaches can be employed to reduce secretion and
extracellular aggregation of destabilized, amyloidogenic protein
variants involved in other systemic amyloid diseases, many of
which have no current therapeutic options (Ryno et al., 2013).
For example, stress-free ATF6 activation selectively reduces
the secretion and extracellular aggregation of destabilized, amy-
loidogenic variants of immunoglobulin light chain (LC) (Cooley
et al., 2014), indicating that this approach has potential to
ameliorate the LC proteotoxicity associated with Light Chain
Amyloidosis, a systemic amyloid disease affecting ten people
per million per year (Blancas-Mejı´a and Ramirez-Alvarado,
2013). The capacity for stress-independent ATF6 activation to
reduce secretion and subsequent extracellular aggregation of
destabilized, amyloidogenic TTR and LC variants, and poten-
tially disease-associated variants of other amyloidogenic pro-
teins (Ryno et al., 2013), bypasses all the challenges associated
with establishing protein specific therapies for each systemic
amyloid disease, potentially allowing a single therapeutic
approach to be broadly applied to these etiologically diverse
diseases of protein aggregation.
SIGNIFICANCE
The results described in this manuscript show that stress-
independent activation of the UPR-associated transcription
factor ATF6 preferentially reduces the secretion and extra-
cellular aggregation of destabilized, aggregation-prone
variants of the amyloidogenic protein TTR, as compared to
stable WT TTR and nonamyloidogenic TTR variants. The
impact of ATF6 activation on TTR variant secretion corre-
sponds with the destabilization of the TTR tetramer afforded
by mutation, indicating that ATF6 activation enhances the
stringency of ER quality control for TTR secretion. The ca-
pacity for ATF6 to preferentially reduce extracellular aggre-
gation of destabilized, disease-associated TTR variants
based on the extent of destabilization suggests that similarElsevier Ltd All rights reserved
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ATF6 Decreases TTR Variant Secretionapproaches can be applied to attenuate the secretion and
extracellular aggregation of destabilized, amyloidogenic var-
iants of other amyloidogenic proteins involved in multiple
systemic amyloid diseases, many of which lack available
treatment options. Thus, ultimately, our results highlight the
therapeutic potential for targeting ATF6 signaling as a
broadly applicable therapeutic strategy to attenuate the
secretion and extracellular proteotoxic aggregation of amy-
loidogenic proteins involved in systemic amyloid diseases.
EXPERIMENTAL PROCEDURES
Cell Culture, Plasmids, and Transfections
HEK293T, HEK293DAX, and HepG2DA cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with glutamine, penicillin/
streptomycin, and 10% fetal bovine serum, as previously described (Shoul-
ders et al., 2013). All TTR point mutations were incorporated into the
FLAG2.TTR.pcDNA3.1 vector (Shoulders et al., 2013) through site-directed
mutagenesis. Transient transfections of FTTTR variants were performed by
calcium phosphate transfection. Adenoviruses for FLAG2.TTR variants were
prepared in the pAD-V5-DEST vector (Life Technologies) and grown and prop-
agated in HEK293A cells (Life Technologies), as previously described (Shoul-
ders et al., 2013). Adenoviruses encoding FTTTR variants were transduced into
HepG2 cells at multiplicities of infection experimentally determined to express
FTTTR mRNA to levels identical to those of the endogenous TTR.
Immunoblotting, Clear-Native-PAGE, and SDS-PAGE
Immunoblotting was performed as previously described and analyzed using
the Li-COR Biosciences Odyssey System (Shoulders et al., 2013). CN-PAGE
was performed on conditioned media prepared on HEK293T or HEK293DAX
cells expressing FTTTR variants as described previously (Wittig and Scha¨gger,
2008) using 4%–16% gradient NativePage gels (Life Technologies), 50 mM
Bis-Tris pH 7.0 anodic buffer, 50 mM Tricine, 15 mM Bis-Tris pH 7.0 cathodic
buffer, and loading buffer containing 5% glycerol, 0.01% Ponceau S, 50 mM
6-aminohexanoic acid, and 10mMBis-Tris pH 7.0. NativeMarkUnstained Pro-
tein Standard (Life Technologies) was used for molecular weight calibration.
SDS-PAGE was performed using freshly prepared 15% tris-glycine gels.
Monoclonal mouse M2 anti-FLAG antibody was purchased from Sigma and
polyclonal rabbit anti-TTR antibody was purchased from Dako.
[35S] Metabolic Labeling Experiments
HEK293DAX or HepG2DA cells plated on poly-D-lysine coated plates were
metabolically labeled in, DMEM-Cys/-Met (CellGro) supplemented with gluta-
mine, penicillin/streptomycin, dialyzed fetal bovine serum, and EasyTag
EXPRESS35S Protein Labeling Mix (Perkin Elmer) for 30 min. Proteasome
and lysosome inhibitors were added at the indicated concentrations 1 hr prior
to metabolic labeling and were included in both the metabolic labeling and
chase. Cells were washed twice with complete media and incubated in pre-
warmed DMEM for the indicated times. Media or lysates were harvested at
the indicated times. Lysates were prepared in radioimmunoprecipitation assay
(RIPA) buffer (150mMNaCl, 50mMTris pH 7.5, 1%Triton X-100, 0.5% sodium
deoxycholate, and 0.1% SDS) with fresh protease inhibitor cocktail (Roche).
FLAG tagged TTR variants were immunopurified using M1 anti-FLAG agarose
beads (Sigma-Aldrich) and washed with RIPA buffer. The immunoisolates were
then eluted by boiling in Laemmli buffer and separated on SDS-PAGE. The gels
were then dried, exposed to phosphorimager plates (GE Healthcare), and
imaged with a Typhoon imager. Band intensities were quantified by densitom-
etry in ImageQuant.
Sigmoidal Fitting of Activating Transcription Factor 6-Dependent
Reductions in Transthyretin Secretion
Figure 2A was prepared by fitting the raw data of TTR variant fraction secreted
at t = 4 hr versus the variant CSS in Kaleidograph using the following
equation: Y(X) = m1 + (m2-m1)/(1+(X/m3)^m4), where m1 is the pretransition
baseline, m2 is the posttransition baseline, m3 is the midpoint of transition,
and m4 is the sharpness of transition. The same equation was used to fit theChemistry & Biology 21, 1564–157raw data of impact of ATF6 activation on TTR variant secretion versus the
variant CSS, as shown in Figure 2B.
Additional experimental procedures are included in the Supplemental
Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.chembiol.2014.09.009.
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